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Abstract 
Hailan Liu 
 
Fatty acid synthase, a novel target for the treatment of 
drug resistant breast cancers 
 
Many cancers, including breast cancer, often develop resistance to 
chemotherapeutic drugs over a course of treatment. Many factors, including 
ABC transporter-mediated drug efflux, have been shown to play a role in 
acquired drug resistance. Fatty acid synthase (FASN), the key enzyme of lipid 
synthesis pathway, was found to be over-produced in an Adiamycin resistant 
breast cancer cell line MCF7/AdrVp3000, compared to its parental drug 
sensitive MCF7 cell line. Inhibition of FASN expression increased the drug 
sensitivity in breast cancer cells (MCF7/AdrVp3000 and MDA-MB-468), but 
not in the normal breast epithelia cell line MCF10A1. Enforced overexpression 
of FASN in MCF7 breast cancer cells decreased its drug sensitivity. These 
results indicated that FASN overexpression can induce drug resistance in 
breast cancers. 
Ectopic overexpression of FASN in MCF7 cells did not affect cell 
membrane permeability, transporter activity, nor did it affect cell proliferation 
rate. However, FASN overexpression protects cancer cells from drug-induced 
apoptosis by decreasing caspase-8 activation. In FASN over-expressing 
 vi
MCF7 cells, I discovered the positive feedback relationship between FASN 
and activation of Akt as previously reported. However, activation of Akt did not 
mediate FASN-induced drug resistance.  
Together with the findings that FASN expression associates with poor 
prognosis in several types of cancers, my investigations suggest that FASN 
overexpression is a novel mechanism of drug resistance in breast cancer 
chemotherapy. Inhibitors of FASN can be used as sensitizing agents in breast 
cancer chemotherapy. 
 
Jian-Ting Zhang, Ph.D., Committee Chairperson 
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 I. Introduction 
Altered metabolism in human cancers has been long recognized. The 
first observation of increased anaerobic glycolysis in cancer was made in 
1920 by Otto Warburg (Warburg, 1956). The so called Warburg effect has 
now become a hallmark of the transformed phenotype, and is thought to 
provide growth advantages to cancer cells (Bui and Thompson, 2006; Shaw, 
2006). Another metabolic hallmark of cancer is an altered lipogenic pathway 
with increased de novo fatty acid synthesis (Kuhajda, 2000). 
Fatty acids serve as important substrates of energy metabolism, 
essential building blocks of cellular membrane, intracellular second 
messengers, and anchorage for membrane proteins. There are two types of 
fatty acids for metabolism, exogenously-derived (dietary) fatty acids and 
endogenously-synthesized fatty acids. The latter is synthesized by fatty acid 
synthase (FASN). In a well nourished individual, cells and tissues 
preferentially use circulating free fatty acids from diet. FASN expression and 
activity are minimal except in some hormone-sensitive cells such as lactating 
breast and cycling endometrium. In these cells, FASN expression is tightly 
regulated by hormonal signals (Kuhajda, 2000).  
In 1994, Kuhajda and colleagues identified oncogenic antigen-519 
(OA-519) – a molecular maker found in breast cancer patients with a 
markedly poorer prognosis – as FASN (Kuhajda et al., 1994). Thereafter, 
increased FASN expression level was found in various human tumors and 
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their pre-neoplastic lesions, including breast, colon, prostate, lung, bladder, 
ovary, stomach, endometrium and many other types of cancers (Kuhajda, 
2000; Kuhajda, 2006; Menendez and Lupu, 2006; Menendez and Lupu, 2007). 
FASN overexpression and hyperactivity is an indicator of tumor 
aggressiveness and poor prognosis in many type of tumors (Kuhajda, 2000; 
Kuhajda, 2006; Menendez and Lupu, 2007). Interrupting the lipogenesis with 
chemical inhibitors of FASN, such as C75 and Orlistat, or by RNA interference 
of FASN expression, has been shown to effectively and selectively kill cancer 
cells (Menendez et al., 2004e; Pizer et al., 2000; Wang et al., 2005; Zhou et 
al., 2003). With the recent published FASN crystal structure (Asturias et al., 
2005; Maier et al., 2006; Maier et al., 2008; Pemble et al., 2007) and the 
development of FASN inhibitors (Alli et al., 2005; Chiang et al., 2007; Kridel et 
al., 2004; Kuhajda et al., 2000), targeting FASN opens a new window of 
opportunity for metabolically combating cancer. 
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A. Structure of mammalian fatty acid synthase 
Human fatty acid synthase (FASN) is a 270 kDa, cytoplasmic enzyme 
(Smith et al., 2003; Wakil, 1989). FASN can be induced to associate 
transiently with lipid raft membranes and form a complex with palmitoylated 
Caveolin-1 in human and murine prostate cancer cells, following the activation 
of upstream signals within the Src, Akt and EGFR family (Di Vizio et al., 2008). 
There is a second gene encoding a mitochondrial FASN (Zhang et al., 2003).  
FASN is a multifunctional polypeptide containing seven catalytic 
domains, which are β-ketoacyl synthase (KS), malonyl/acetyltransferase 
(MAT), dehydrogenase (DH), enoyl reductase (ER), β-ketoacyl reductase 
(KR), acyl carrier protein (ACP) and thioesterase (TE) (Smith, 1994). 
Conventional models of mammalian FASN proposed that FASN formed a fully 
extended head-to-tail homodimer. However, results from mutant 
complementation, chemical crosslinking and monomer interaction were 
imcompatible with the classical model. Therefore, a revised model was 
proposed, in which FASN forms an interwined head-to-head dimer. Each 
monomer in the dimeric form of FASN adopts a coiled conformation that 
allows multiple intra- and inter-monomer functional domain interaction, with 
the KS domains located in the central portion of the structure. This model was 
further supported by the results from cryo-electron microscopy and crystal 
structure studies (Asturias et al., 2005; Maier et al., 2006; Maier et al., 2008). 
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Figure 1. Two models for domain organization of FASN. (a) In the 
conventional model, two monomers in the homodimeric form of FASN are 
arranged in a fully extended head-to-tail orientation (b) A revised model for 
FASN, which shows an X-shaped dimeric form with each monomer adopts a 
coiled structure to allow multiple intra- and inter-molecular interaction.  FASN 
catalytic domains, starting from the N-terminus, are ketoacyl synthase (KS), 
malonyl/acetyltransferase (MAT), dehydrase (DH), enoyl reductase (ER), 
-ketoacyl reductase (KR), acyl carrier protein (ACP) and thioesterase (TE).
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B. Brief overview of the fatty acid synthesis pathway 
Although the synthesis of fatty acids from glucose involves about 25 
enzymes, the main synthetic pathway is comprised of the following key 
elements: 1) acetyl-CoA carboxylase, which carboxylates acetyl-CoA to 
malonyl-CoA and is the rate limiting enzyme of fatty acid synthesis pathway; 2) 
citrate lyase, which converts citrate to acetyl-CoA; 3) nicotinamide adenine 
dinucleotide phosphate (NADPH), used as reducing equivalents; and 4) 
FASN, the enzyme that condenses acetyl-CoA and malonyl-CoA to 16-carbon 
palmitate. The whole fatty acid synthesis pathway consumes 14 ATP and 7 
NADPH per fatty acid synthesized. (Figure 2) 
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Figure 2. Fatty acid synthesis pathway. The fatty acid synthesis pathway 
functions in both cancers and lipogenic tissue. In both cases, excess glucose 
goes through glycolysis and TCA cycle, and exits the mitochondria as citrate. 
Citrate is transported out of mitochondria and converted to acetyl-CoA, which 
is then carboxylated to malonyl-CoA by Acetyle-CoA carboxylase (ACCα). 
FASN condenses one acetyl-CoA and seven malonyl-CoA into palmitate. 
Palmitate is then modified by various enzymes into various lipids such as 
phospholipids. Besides its role as FASN substrate, malonyl-CoA inhibits 
CPT-1 and thus prevents fatty acid oxidation.
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       Although the fatty acid synthesis pathway is identical in cancer cells 
and normal lipogenic tissues, the difference lies in the following three aspects:  
1. The fate of palmitate, the end product of the fatty acid synthesis 
pathway, is different between lipogenic tissue and cancer cells. In 
lipogenic tissues, fatty acid synthesis occurs as a mean to store 
excess energy from carbohydrate, which is converted to 
triacylglycerol (McGarry and Brown, 1997). High level of malonyl-CoA 
during lipogenesis inhibits mitochondrial fatty acid oxidation, directing 
fatty acids to storage. During starvation, FASN expression and activity 
is rapidly down-regulated, malonyl-CoA levels decrease, and fatty 
acid oxidation is initiated to ensure survival. On the other hand, 
endogenously synthesized fatty acids in cancer cells are mainly 
converted to phopspholipid and incorporated into the cell membranes 
(Swinnen et al., 2003). 
2. The regulation of FASN is different. In a well fed animal, diet is the 
main regulator of FASN, except in lactating breast and cycling 
endometrium, where FASN expression is under the tight hormonal 
control of estrogen and progesterone (Kuhajda, 2000). In contrast, 
FASN expression in cancer cells is transcriptionally regulated by 
either hormonal signals or aberrant growth factor signaling in cancer 
cells (Porstmann et al., 2005; Swinnen et al., 2000; Yoon et al., 2007; 
Zhang et al., 2005). 
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3. The consequence of FASN inhibition differs significantly between 
cancer cells and normal cells. FASN inhibition by either inhibitor or 
siRNA induces apoptosis selectively in human cancer cells both in 
vitro and in vivo (De Schrijver et al., 2003; Menendez et al., 2004a; 
Menendez et al., 2004c; Zhou et al., 2003), but not normal cells 
(Browne et al., 2006; Chajes et al., 2006; Liu et al., 2008). 
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C. FASN expression in cancers.  
High level of FASN expression has been found in many types of 
cancers and their pre-neoplastic lesions, including breast, prostate, ovary, 
lung, colon etc. (Kuhajda, 2006; Menendez and Lupu, 2007). Elevated FASN 
levels have also been identified in the blood of patients with breast, prostate, 
colon, and ovarian cancers compared with normal subjects using ELISA 
(Wang et al., 2004). High FASN expression associates with poor prognosis in 
some type of cancers including breast, prostate, ovarian, stage I non-small 
cell lung cancer, malignant melanoma and soft tissue sarcoma (Kuhajda, 
2000; Kuhajda, 2006). FASN expression and activity clearly confer growth 
advantages in human cancers and can be developed as a marker for cancer 
detection, prognosis and monitoring.  
FASN expression in normal liver and adipose tissue is controlled by 
nutritional signals. Carbohydrate ingestion, thyroid hormone, insulin, and 
glucocorticoid coordinately upregulate FASN expression, while unsaturated 
fatty acids, cyclic-AMP, and glucagon downregulate FASN expression. In 
lactating breast and cycling endometrium, FASN expression is tightly 
regulated by estrogen and progestin (Kuhajda, 2000).  
FASN expression in cancer is no longer responsive to the nutritional 
signals. In breast and prostate cancers that have functional hormone 
receptors, FASN expression was shown to be up-regulated upon hormone 
treatment (Chalbos et al., 1987; Menendez et al., 2005b; Swinnen et al., 
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1997). However, in prostate cancer cells following androgen ablation, FASN 
expression initially decreased, only to return at higher levels following 
androgren ablation (Ettinger et al., 2004; Pizer et al., 2001). These results 
indicate that cancer cells may have novel regulatory pathways for FASN 
expression in cancer cells.  
Cancer cells have at least two levels of regulation for FASN 
expression. At the transcriptional level, growth factors (GF) and growth factor 
receptors (GFR) have been shown to be the main contributors to FASN 
overexpression. Epidermal growth factor (EGF) can stimulate FASN 
overexpression through EGF receptor ERBB1 and ERBB2 (Kumar-Sinha et 
al., 2003; Swinnen et al., 2000; Zhang et al., 2005). The effect of GFs and 
GFRs on FASN expression involves complicated downstream signaling and 
cross-talk between multiple signal transduction pathways. The 
mitogen-activated protein kinase (MAPK) pathway has been shown to be 
involved in FASN expression regulation (Gao et al., 2006; Menendez et al., 
2004c). The role of the PI3K/Akt pathway in FASN expression has been well 
studied (Chiang et al., 2007; Furuta et al., 2008; Hughes-Fulford et al., 2006; 
Pan et al., 2007; Porstmann et al., 2005; Uddin et al., 2008; Van de Sande et 
al., 2002; Van de Sande et al., 2005; Wang et al., 2005; Weng et al., 2007; 
Yang et al., 2002b). High levels of FASN expression were linked to activation 
and nuclear localization of Akt in human prostate cancer tissues (Van de 
Sande et al., 2005). Similarly, FASN overexpression was shown to be 
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associated with activated AKT in papillary thyroid cancer tissue using 
microarray analysis (Uddin et al., 2008). Inhibitors of PI3K pathway can 
decrease FASN expression, yet loss of PTEN (phosphatase and tensin 
homologe) and subsequently constitutive activation of Akt has been shown to 
correlate with increased FASN expression in prostate and ovarian cancer 
cells (Van de Sande et al., 2002; Wang et al., 2005). A transcriptome analysis 
of Her2 (ERBB2) in breast cancer cells revealed a molecular connection 
between FASN and Her-2 through PI3K-Akt-dependent signaling 
(Kumar-Sinha et al., 2003). GFs signal through MAPK and PI3K/Akt pathways, 
affecting FASN expression by modulation of a transcription factor, sterol 
regulatory element binding protein-1c (SREBP1c) (Ettinger et al., 2004; 
Furuta et al., 2008; Porstmann et al., 2005; Yang et al., 2002b; Yang et al., 
2003). Analysis of breast cancer tissues for FASN and SREBP1c mRNA 
revealed a coordinate regulation of tumor-associated FASN and other 
lipogenic enzymes by SREBP1c (Yang et al., 2003), further supporting the 
role of SREBP1c in FASN expression regulation. Steroid hormones (SHs), 
including estrodial, progestins and androgens, also regulate FASN expression 
in hormone responsive cancers through aberrant activation of PI3K/Akt and 
MAPK pathways (Chalbos et al., 1987; Menendez et al., 2005b; Swinnen et 
al., 1997). 
A lack of correlation between FASN gene amplification and FASN 
protein expression was observed in some prostate cancer cell lines and 
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tissues (Shah et al., 2006), suggesting the presence of post-translational 
regulation. In prostate cancer cells, FASN protein stability has been shown to 
be regulated by an ubiquitin-specific protease, USP2a (Graner et al., 2004). 
Knockdown of USP2a reduced FASN expression, decreased cell proliferation, 
and induced apoptosis. Microarray analysis from human prostate cancers has 
revealed a significant association between the genes in FA metabolism and 
high USP2a expression (Priolo et al., 2006). 
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D. FASN as a target for cancer chemotherapy 
The differences in the FASN expression level between normal and 
cancer cells, together with the specific cytotoxicity of FASN inhibition in 
cancer cells, led to the exploration of FASN as a therapeutic target for cancer 
treatment.  
 How FASN overexpression affects the progression and potential 
response of cancer cells to chemotherapy is not fully understood. Results 
from the study of the cytotoxic effect of FASN inhibition helps to unveil the 
possible functions of FASN in cancer. Several mechanisms have been 
proposed to explain the apoptosis following FASN inhibition.  
1. Toxicity from malonyl-CoA accumulation 
FASN inhibition causes accumulation of its substrate malonyl-CoA. 
Studies showed that FASN inhibition induced apoptosis, while acetyl-CoA 
carboxylase (ACCα) inhibition depleted malonyl-CoA and protected cancer 
cells from apoptosis (Chajes et al., 2006; Pizer et al., 2000; Thupari et al., 
2001). These results suggested that malonyl-CoA accumulation led to cancer 
cell death. The accumulation of malonyl-CoA inhibits fatty acid β-oxidation by 
inhibiting mitochondria outer membrane protein CPT-1 
(carnitine-palmitoyltransferase 1), which in turn promotes accumulation of 
ceramide, followed by the induction of pro-apoptotic genes (such as BNIP3, 
TRAIL, and DAPK2) (Bandyopadhyay et al., 2006).  
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2. Disturbance of membrane lipid domain 
       Inhibition of FASN mainly affects the synthesis of phospholipids that 
incorporate into a detergent-resistant membrane microdomain (lipid raft 
aggregates), but has a lesser effect on the synthesis of non-raft associated 
lipids (Swinnen et al., 2003). It is implied that FASN expression levels in 
colonic adenocarcinoma may contribute to the increased ratio of saturated to 
unsaturated C18 FAs, and thus affect the structure and function of lipid rafts 
(Rakheja et al., 2005). Many proteins involved in signal transduction, 
apoptosis, membrane transport, and cell adhesion, are associated with lipid 
rafts (Bollinger et al., 2005; Pike, 2003; Simons and Ikonen, 1997). Changes 
in lipid rafts associated with FASN overexpression in cancer cells are likely to 
affect the signaling proteins residing in the raft in a way to enhance cancer cell 
survival and resistance to drug-induced apoptosis.  ERBB2 (Her2) is one of 
the most important oncogenes in breast cancer. It is a receptor tyrosine 
kinase which co-localizes with lipid rafts (Menendez et al., 2005e). It has been 
shown that Her2 regulated FASN expression (Kumar-Sinha et al., 2003; 
Menendez et al., 2005a; Menendez et al., 2005d; Menendez et al., 2006c; 
Yoon et al., 2007; Zhang et al., 2005), while FASN inhibition decreased Her-2 
expression (Chiang et al., 2007; Menendez et al., 2004d; Menendez et al., 
2006a; Menendez et al., 2005d; Menendez et al., 2005e; Menendez et al., 
2006b; Menendez et al., 2004e; Vazquez-Martin et al., 2007a) and sensitized 
Her-2 positive cancers to Taxol and vinorelbine, 5-fluorouracil and Herceptin 
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(Menendez et al., 2004a; Menendez et al., 2004b; Vazquez-Martin et al., 
2007a; Vazquez-Martin et al., 2007b). Clinical studies have also 
demonstrated the linkage between FASN, Her2 and cancer malignancy 
(Sebastiani et al., 2006; Silva et al., 2004; Silva et al., 2008a; Silva et al., 
2008b). Most recently, Menendez and colleagues further demonstrated that 
enforced ectopic overexpression of FASN in breast epithelia cells can activate 
Her1/Her2, suggesting that increased de novo synthesis of fatty acids by 
FASN significantly affects the formation of Her1/Her2 signaling complexes at 
the cell membrane (Vazquez-Martin et al., 2008). Inhibition of FASN is a 
promising new strategy to overcome the drug resistance in Her-2 
over-expressing breast cancers 
3. Inhibition of cell proliferation 
FASN inhibition has major influence on the synthesis of 
phopspholipids (Jackowski, 1994; Swinnen et al., 2003), which are important 
for cell proliferation in two aspects. First, phopspholipids are major 
components of cellular membranes.  FASN inhibition, thus, affects the 
synthesis of cellular membranes in highly proliferating tumor cells (Pizer et al., 
1996b). Second, phopspholipid biosynthesis is greatest during the G1 and S 
phase of the cell cycles in preparation for cell division (Jackowski, 1994). 
Inhibiting FASN produces rapid, potent inhibition of DNA replication, which 
arrests the cell cycle at the G1/S transition by affecting p21, p27, BRCA1, 
skp2, and NF-κB (Knowles et al., 2004; Knowles and Smith, 2007; Li et al., 
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2001; Menendez et al., 2004c; Pizer et al., 1998; Zhou et al., 2003). The 
tumor suppressor gene p53 is the decision maker between apoptosis and 
growth arrest following FASN inhibition. FASN inhibition is more effective in 
initiating apoptosis in cells with non-functional p53, while in cells with 
functional p53, FASN inhibition is more likely to produce a cytostatic response 
(Li et al., 2001).   
4. Inhibition of cell survival pathways. 
Activation of the PI3K/Akt survival pathway is very important for 
cancer cell survival, proliferation, invasiveness and potential responses to 
chemo-and radiation therapy (Hu et al., 2002; Page et al., 2000; Testa and 
Bellacosa, 2001). It is well established that activation of the PI3K/Akt pathway 
can increase FASN expression in human cancers in vivo and in vitro (Chiang 
et al., 2007; Furuta et al., 2008; Hughes-Fulford et al., 2006; Pan et al., 2007; 
Porstmann et al., 2005; Uddin et al., 2008; Van de Sande et al., 2002; Van de 
Sande et al., 2005; Wang et al., 2005; Weng et al., 2007; Yang et al., 2002b). 
Inhibition of the PI3K/Akt pathway by LY 294002 abolished pAkt activity and 
sensitized human ovarian and breast cancer cells to FASN inhibitor induced 
apoptosis (Liu et al., 2006a; Wang et al., 2005), indicating that active Akt 
protects cancer cells against FASN inhibitor induced apoptosis. Furthermore, 
inhibition of FASN activity caused a decrease in the level of 
phosphorylated-Akt, which proceded the induction of apoptosis both in vitro 
and in vivo (Alli et al., 2005; Menendez et al., 2004d; Menendez et al., 2005c; 
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Orita et al., 2008; Wang et al., 2005; Yeh et al., 2003).  
In summary, FASN overexpression confers cancer cells distinct 
growth advantages by modulating lipid raft domains in a way to promote cell 
growth, activate cell survival and proliferation signals, and/or prevent 
apoptosis by inhibiting the pro-apoptotic signals. Further studies of FASN 
inhibition in cancer cells will help to discover the pathways that modulate cell 
survival and/or apoptosis, and assist the development of better treatment 
regimens for cancers.
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E. FASN inhibitors 
Numerous in vivo and in vitro studies have confirmed the potential of 
FASN inhibitors as a novel antitumor treatment. FASN inhibitors such as 
cerulenin and its derivatives, C75 and C93, FDA approved anti-obesity drug 
Orlistat, the green tea polypenol epigallocatechine-3-gallate (EGCG) and 
other naturally occurring flavonoids, as well as the antibiotic triclosan, have 
been shown to induce cancer cell apoptosis. 
The small molecule FASN inhibitor C75 was designed based on 
cerulenin (Kuhajda et al., 2000). C75 is more chemically stable than cerulenin, 
and showed significant antitumor effects on cancer cell lines of human breast 
(Pizer et al., 2000), prostate (Pizer et al., 2001), mesothelioma (Gabrielson et 
al., 2001), ovarian (Wang et al., 2005), and renal carcinoma xenografts 
(Horiguchi et al., 2008). Besides its inhibitory effect on FASN, C75 also 
increases fatty acid oxidation through direct activation of CPT-1 (Cha et al., 
2005; Kuhajda et al., 2005; Landree et al., 2004; Nicot et al., 2004; Puig et al., 
2008; Thupari et al., 2002; Yang et al., 2005) It also reduces food intake by 
blocking the production of hypothalamic neuropeptide-Y, which causes 
substantial weight loss in experimental animals (Thupari et al., 2004).  
A newer generation of cerulenin derivatives, C93, was rationally 
designed and showed a FASN inhibitory effect without parallel stimulation of 
fatty acid oxidation in a preclinical model of lung cancer (Orita et al., 2007; 
Orita et al., 2008; Zhou et al., 2007). Cerulenin, C75 and C93 all target the 
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keto-acyl synthase domain of FASN (Christie et al., 1981; Kuhajda et al., 2000; 
Rendina and Cheng, 2005) 
Orlistat is a newly discovered FASN inhibitor (Kridel et al., 2004). 
Originally a US Food and Drug Administration (FDA) approved anti-obesity 
drug. Orlistat works primarily on pancreatic and gastric lipase within the 
gastrointestinal (GI) tract (McNeely and Benfield, 1998). In 2004, Orlistat was 
first found to inhibit FASN in an activity-based screening for inhibitors of serine 
hydrolases in prostate cancer cells (Kridel et al., 2004). Studies from several 
groups demonstrated that Orlistat exhibits antitumor effects toward melanoma, 
breast and prostate cancer cells in vitro and in vivo by inhibiting FASN activity 
(Browne et al., 2006; Carvalho et al., 2008; Knowles et al., 2004; Knowles et 
al., 2008; Kridel et al., 2004; Little et al., 2007; Liu et al., 2008; Lupu and 
Menendez, 2006; Menendez et al., 2005d). Orlistat treatment induces 
endoplasmic reticulum stress in tumor cells (Little et al., 2007), inhibits 
endothelial cell proliferation and angiogenesis (Browne et al., 2006). Recent 
co-crystalization of the FASN thioesterase domain and Orlistat, together with 
a molecular docking study, proved that Orlistat binds and inhibits FASN 
thioesterase activity (Cheng et al., 2008; Pemble et al., 2007). These studies 
provide useful information for structure-based drug design targeting FASN. 
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F. Specific aims of the present work 
One of the major problems in successful treatment of breast cancer is 
development of multidrug resistance that reduces the effectiveness of 
chemotherapy. Breast cancer cells can be either intrinsically drug resistant, or 
sometimes acquire drug resistance following chemotherapy. Research results 
from drug resistant model cell lines indicated that expression of plasma 
membrane glycoproteins, such as P-glycoprotein (Pgp or MDR1), multidrug 
resistance protein 1 (MRP1), and breast cancer resistance protein (BCRP), is 
a frequent cause of MDR (Allen et al., 1999; Ambudkar et al., 1999; Bellamy, 
1996; Cole et al., 1992; Doyle et al., 1998; Endicott and Ling, 1989; 
Gottesman et al., 2002; Miyake et al., 1999). Cancer cells over-expressing 
Pgp, MRP1, or BCRP have an ability to extrude a wide variety of unrelated 
cytotoxic drugs and, therefore, can survive chemotherapy.    
To study the mechanisms of drug resistance, many resistant cell lines 
were established in vitro by selection with various anticancer agents. A series 
of drug resistant breast cancer cell lines (see Table 1) were generated by 
stepwise selection of the drug sensitive breast cancer cell line MCF7 with 
increasing concentrations of Adriamycin in the presence of verapmil (Chen et 
al., 1990; Litman et al., 2000), a MDR/MRP1 inhibitor. MCF7/AdrVp3000 cells 
showed the highest level of resistance, and the overexpression of BCRP in 
this cell line was thought to be the mechanism of drug resistance (Doyle et al., 
1998; Miyake et al., 1999). Indeed, the enforced ectopic expression of BCRP 
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in MCF7 cells showed the same pattern of drug resistance as 
MCF7/AdrVp3000 cells. However, the drug resistance level was much lower 
in BCRP over-expressing MCF7 cells than that of MCF7/AdrVp3000 cells, 
even though steady-state BCRP levels in both cell lines are comparable. This 
result suggests that mechanisms other than BCRP overexpression also 
contribute to the higher drug resistance level in MCF7/AdrVp3000 cells. In 
fact, genomic profiling of ABC transporters (Liu et al., 2005) and a proteomic 
study (Liu et al., 2006b) performed by our lab discovered numerous proteins 
other than BCRP, which may contribute to the drug resistance phenotype in 
MCF7/AdrVp3000 cells. 
 
Table 1. Summary of MCF7 and its derivative drug resistant cell lines 
  Resistance to 
Cell lines Selected with      
Adriamycin 
       
Mitoxantrone 
MCF7 (parental) N.A. N.A. N.A. 
MCF7/AdrVp10 10ng/ml Adr/10ng/ml VP Yes N.D. 
MCF7/AdrVp100 100ng/ml Adr/10ng/ml VP Yes Yes 
MCF7/AdrVp3000 3000ng/ml Adr/10ng/ml VP Yes Yes 
MCF7/BCRP (tansfected) N.A. Yes Yes 
               N.A.=not applicable; N.D.=not determined; Adr=Adriamycin; VP=verapamil 
Our preliminary data showed that FASN expression is elevated in 
drug resistant breast cancer cell lines and this overexpression correlates with 
the increased drug resistance of these cells. These observations suggest that 
FASN overexpression in breast cancer cells may cause resistance to 
chemotherapy. Indeed, a previous clinical analysis suggested that high levels 
of FASN expression associates with poor prognosis of breast cancer patients 
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(Alo et al., 1999). My study was designed to investigate the mechanism of 
FASN-mediated drug resistance in breast cancers. Two specific aims are 
addressed in the present work.  
The first aim is to determine if FASN overexpression contributes to the 
drug resistance phenotype in breast cancer cells. Using the sulfarhodamine-B 
cytotoxicity assay, we showed that down-regulating FASN in drug resistant 
MCF7/AdrVp3000 cells decreased their resistance to Adriamycin and 
mitoxantrone, while ectopic overexpression of FASN in parental drug sensitive 
MCF7 cells increased their resistance to a panel of DNA damaging drugs, 
such as Adriamycin, mitoxantrone, etopside, camptothecin, and cisplatin. The 
FASN overexpression-induced increase in drug resistance is not limited to 
MCF7 cells alone, but is observed in the MDA-MB-468 breast cancer cell line 
as well. Down-regulation of FASN did not affect the drug resistance 
phenotype in the normal breast epithelia cell line MCF10A1. 
The second aim is to investigate the detailed mechanism of 
FASN-induced apoptosis in breast cancer cells. Our findings suggest that 
FASN overexpression protects cancer cells from drug-induced apoptosis by 
inhibiting caspase-8 activation.  
The outcome from this study should lead to a better understanding of 
how FASN contributes to the malignancy of cancer cells, and thus help to 
develop better antineoplastic drugs and treatment regimens that maybe more 
effective for drug resistant breast cancers.  
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II. Materials and Methods 
A. Materials 
All electrophoresis reagents, precast slab gel and polyvinylidene 
difluoride (PVDF) membrane were purchased from Bio-Rad (Hercules, CA). 
Adriamycin, mitoxantrone, vinblastine, paclitaxel, cisplatin, camptothecin, 
etopside, verapmil, dithiothreitol (DTT), Insulin, epithelial growth factor (EGF), 
Cholera enterotoxin and hydrocortisone were purchased from Sigma (St. 
Louis, MO). Orlistat (Xenical) was obtained from Roche Laboratories Inc 
(Nutley, NJ). SYBR Green PCR master Mix for real-time PCR was purchased 
from Applied Biosystems (Foster City, CA). Monoclonal antibody against fatty 
acid synthase (FASN) was purchased from BD Biosciences (San Jose, CA). 
Antibodies to phosphor-AKT, total AKT, cleaved PARP, Caspase-8 and 
Caspase-9 were purchased from Cell Signaling (Danvers, MA). Monoclonal 
antibody to FLIP (NF6) was purchased from Alexis Biochemicals (San Diego, 
CA). siRNA with scrambled sequence (scrambled siRNA) was purchased from 
Ambion (Austin, Texas). Lipofectamine 2000, Lipofectamine Plus and G418 
were purchased from Invitrogen (Carlsbad, CA). FuGene 6 was purchased 
from Roche Applied Sciences (Indianapolis, IN). ECL Western Blotting 
detection reagents and SuperSignal West Dura extended duration substrate 
were purchased from GE Healthcare (Pittsburg, PA) and Thermo Scientific 
(Rockford, IL), respectively. Cell culture mediums IMEM, Opti-MEM, DMEM, 
DME/F12 50/50, fetal bovine serum, equine serum, and typsin-versene 
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mixture were purchased from BioSources International (Camarillo, CA), 
Media Tech (Herndon, CA), or Cambrex (Walkersvill, MD). All other chemicals 
were of molecular biology grade from Sigma (St. Louis, MO) or Fisher 
Scientific (Chicago, IL).  
B. Cell cultures 
Human breast cancer cell line MCF7 and its drug-resistant derivative 
cell lines MCF7/AdrVp10, MCF7/AdrVp100, and MCF7/AdrVp3000 (gifts from 
Dr. Susan E. Bates, National Cancer Institute, Bethesda, MD) were cultured at 
37°C with 5% CO2 in DMEM or IMEM medium, supplemented with 10% fetal 
bovine serum, 100 units/ml penicillin, 100 µg/ml streptomycin as previously 
described (Chen et al., 1990; Lee et al., 1997; Litman et al., 2000; Liu et al., 
2006b). To maintain the drug resistance phenotype of MCF7/AdrVp10, 
MCF7/AdrVp100, and MCF7/AdrVp3000 cells, 10, 100, and 3,000 ng/ml 
Adriamycin were included, respectively, together with 5 µg/ml verapamil. 
MDA-MB-468 cell line was cultured in DMEM supplemented with 10% fetal 
bovine serum, 100 units/ml penicillin, and 100 mg/ml streptomycin. MCF10A1 
cell line (Karmanos Cancer Institute) was cultured in DME/F12 50/50 with 
10% equine serum, 10 µg/ml insulin, 25 ng/ml EGF, 500 ng/ml hydrocortisone 
and 100 ng/ml cholera enterotoxin.  
C. Stable cell transfection 
To establish MCF7/AdrVp3000 stable cell clones with reduced FASN 
expression, a plasmid which expresses short hairpin RNAs (shRNA) 
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specifically targeting FASN with a sequence of 
AACCCTGAGATCCCAGCGCTG or a scrambled control sequence was 
transfected into MCF7/AdrVp3000 cells using FuGene 6 Transfection 
Reagents according to manufacture’s suggestions. Twenty-four hours 
following transfection, the cells were cultured in the presence of 800 µg/ml 
G418 for 2 weeks. Individual stable clones selected were expanded and 
maintained in the presence of 200 µg/ml G418 for further analyses. 
To establish MCF7 stable clones with ectopic overexpression of FASN, 
the cDNA encoding human FASN (a gift from Dr. Massimo Loda, Dana Farber 
Cancer Institute) was engineered into the pcDNA3 vector and transfected into 
MCF7 cells using FuGene 6 according to manufacturer's suggestions. Two 
days following transfection, 10% of the transfected cells were replated and 
selected with 800 µg/ml G418 for 2 weeks, and stable clones were 
propagated and maintained in the presence of 200 µg/ml G418 for further 
analyses 
D. siRNA preparation and transfection 
siRNAs targeting FASN (AACCCTGAGATCCCAGCGCTG) and the 
negative control siRNA with scrambled sequence (scrambled siRNA) were 
synthesized by Ambion (Austin, Texas) as previously described (De Schrijver 
et al., 2003). For siRNA transfection, 5 x 105 MDA-MB-468 cells or MCF10A1 
cells were plated in a 6-well plate for 24 hours, followed by transfection with 
siRNAs using Lipofectamine 2000 reagent according to supplier's instructions. 
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Briefly, 5 µl of Lipofectamine 2000 was diluted with 100 µl of Opti-MEM 
medium and incubated at room temperature for 5 min. Two hundred 
picomoles of siRNAs were added to 100 µl of Opti-MEM medium and then 
mixed with the diluted Lipofectamine 2000 reagent followed by incubation at 
room temperature for 25 min. The siRNA-Lipofectamine 2000 reagent 
complex was added drop-wise into the culture containing 0.8 ml of fresh media. 
At different days following transfection, cell lysates were prepared for 
detection of FASN by Western blot analysis.  
E. Cell lysate preparation  
Cells were harvested and washed with phosphate-buffered saline and 
then lysed in lysis buffer (50 mM Tris pH 7.4, 150 mM NaCl, 0.5% NP-40, 
20mM EDTA, pH 8.0, 1 mM sodium orthovanadate, 50mM sodium fluoride, 2 
mM phenylmethylsulfonyl fluoride, and 1mM dithiothreitol) for 30 min on ice 
with constant agitation. The cell lysates were sonicated briefly followed by 
centrifugation (16,000g, 4°C) for 15 min to remove insoluble materials. The 
protein concentration of cell lysates was determined using BioRad protein 
assay kit. 
F. Western blot analysis 
Western blot analysis was performed as described previously 
(Pincheira et al., 2001; Yang et al., 2002a; Zhang et al., 1993). Briefly, cell 
lysates were separated by SDS-polyacrylamide gel electrophoresis 
(SDS-PAGE) followed by transfer to a PVDF membrane. The blot was then 
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probed with an antibody to specific proteins (diluted according to 
manufacturer’s suggestion), followed by reaction with horseradish 
peroxidase-conjugated secondary antibodies. The signal was captured by 
X-ray film or FluorChem HD2 immaging system (Alpha Innotech) using 
Amsham ECL Western Blot detection agents or Pierce Supersignal West 
Dura Extended Duration substrate. 
G. FASN activity assay 
FASN activity was determined using a protocol as previously 
described (Menendez et al., 2004c). Briefly, 96 µg of particle-free supernatant 
of cell lysate was mixed with a buffer containing 200 mM potassium 
phosphate, pH 6.6, 1 mM DTT, 1 mM EDTA, 0.24 mM NADPH and 30 µM 
acetyl-CoA in a final volume of 0.2 ml and the reaction was monitored at 340 
nm for 3 min to measure background NADPH oxidation. After the addition of 
50 µM of malonyl-CoA, the reaction was assayed for an additional 15 min to 
determine FASN-dependent oxidation of NADPH. The rates of OD340nm 
change were corrected for the background rate of NADPH oxidation. FASN 
activity was expressed as nmoles NADPH oxidized/min/mg protein.  
H. Cytotoxicity assay 
Cytotoxicity of various anti-cancer drugs to cancer cells was 
determined using the sulforhodamine B (SRB) colorimetric assay as 
previously described (Liu et al., 2006b) with some modification. Briefly, cells 
were seeded in 96-well plates in triplicate and cultured at 37°C for 24 hours 
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before drugs were added. Cells were then cultured continuously at 37°C until 
the control cells became confluent (usually 72-96 hours) before SRB assay. 
For the study of the palmitic acid effect, Adriamycin or mitoxantrone was 
added to the cells 24 hours after incubation with 100 µM of palmitic acid 
(Chajes et al., 2006). For the study of the Orlistat effect, Adriamycin was 
added to the cells in the presence or absence of 30 µM Orlistat for 3 days 
before SRB assay (Kridel et al., 2004). 
 For the SRB assay (Skehan et al., 1990), the culture medium was 
removed and the cells were fixed and stained by addition of 0.4% (w/v) 
sulforhodamine B (Sigma) in 1% acetic acid solution followed by incubation at 
room temperature for 20 minutes. The plates were then washed three to five 
times with 1% acetic acid to remove the unbound SRB and then air-dried at 
room temperature. The bound SRB was then solubilized with 10 mM 
unbuffered Tris base. The OD570 nm was determined using a 96-well plate 
reader (MRX; Dynex Technologies, Chantilly, VA). IC50 was defined as the 
concentration of drugs required to kill 50% of the cells relative to control 
condition without drugs. 
I. Cell growth analysis 
Cell growth rate was determined as previously described (Dong et al., 
2004). Briefly, MCF7 and its derivative stable clones transfected with FASN 
cDNA were plated at 150 cells/well whereas MCF7/AdrVp3000 and its 
derivative stable clones transfected with shRNA were plated at 250 cells/well 
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in triplicate in 96 wells, respectively. Plates were collected every other day 
followed by removal of media and the fixation of cells with 100 µl/well of 1% 
glutaraldehyde for 30 minutes at room temperature. The plates were then 
washed 3 times with 200 µl PBS and air dried. Crystal violet solution (100 
µl/well, 0.2% crystal violet in 20% methanol) was then added to the air-dried 
plates and incubated for 30 minutes at room temperature. The plates were 
then washed extensively with water to remove excess dye and air dried again. 
To dissolve the dye, 200 µl of 10% acetic acid was added to each well and the 
plates were incubated for 1 hour with shaking at room temperature. Finally, 
OD 570nm was determined. 
J. Drug uptake assay 
The drug uptake assay was performed as described previously with 
some modification (Lee et al., 1994). Briefly, 5×105 cells were resuspended in 
0.5 ml PBS containing 20 µl mitoxantrone (20 µM) and incubated at 37°C for 
30 minutes. Cell were then collected by centrifugation and washed twice with 
PBS followed by analysis using flow cytometry on a Becton Dickinson 
FACScalibur. The data were analyzed using Cell Quest Pro (BD Bioscience). 
K. Co-immunoprecipitation 
To preclear the samples, 400 µg cell lysate was diluted in 0.5 ml TNN 
buffer (1% Triton X-100, 150 mM NaCl, 10 mM Tris pH 7.4, 1 mM EDTA, 1 mM 
EGTA, pH 8.0, 0.2 mM sodium orthovanadate, 0.2 mM phenylmethylsulfonyl 
fluoride, 0.5% NP-40, and 0.1% SDS), mixed with 1 µg normal mouse IgG, 
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and 40 µl Protein G-Sepharose beads, and then incubated at 4°C for 2 hours. 
After incubation, the mixture was centrifuged at 5000 rpm for 30 seconds, the 
supernatant was transferred to a new tube and incubated with primary 
antibodies for 3 hours at 4°C. 50 µl of Protein G-Sepharose beads was then 
added to the tube and incubated overnight at 4°C. The immunoprecipitates 
were then collected by centrifugation, washed 5 times with 1 ml TNN buffer, 
and finally solublized in 40 µl SDS-PAGE sample buffer for Western blot 
analysis. 
L. Real-time quantitative reverse transcription-PCR 
Total RNAs were isolated from cultured cells using a RNeasy mini kit 
according to the manufacturer’s instruction (Qiagen, Valencia, CA) and 
treated with RQ1 RNase-free DNase I. Four micrograms of total RNA each 
were reverse transcribed using avian myeloblastosis virus Reverse 
Transcriptase and Oligo(dT)12-18 primer (Invitrogen). Primers for real-time 
PCR were designed using Primer Express software version 2.0 (Applied 
Biosystem) and were synthesized by Invitrogen. The primer sequence for 
FASN are 5’-GCTGACCCCAGGCTGTGA-3’ (forward) and 
5’-TGCTCCATGTCCGTGAACTG-3’ (reverse). The primer sequences for 
internal control glycerolaldehyde-3-phosphate dehydrogenase (GAPDH) are 
5’-AAGGACTCATGACCACAGTCCAT-3’ (forward) and 
5’-CCATCACGCCACAGTTTCC-3’ (reverse). Real-time quantitative PCR was 
performed on an ABI prism@7000 Sequence Detection System (Applied 
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Biosystems) using SYBR Green diction according to the manufacturer’s 
instruction. The threshold cycle (Ct) was defined as the PCR cycle number at 
which the reporter fluorescence crosses the threshold reflecting a statistically 
significant point above the calculated baseline. The Ct of FASN was 
determined and normalized against that of the internal control housekeeping 
gene GAPDH. The relative level calculated against that in MCF7 cells = 2∆∆Ct 
M. DNA fragmentation assay.  
FASN over-expressing MCF7 cells and vector-transfected control 
cells were grown in twenty four-well plates and were incubated with 1 µM 
Adriamycin for 48 hours. Cells were harvested to assess DNA fragmentation 
using the Cell Death Detection ELISA (Roche, Mannheim, Germany) 
according to the manufacturer’s recommendations. The cytosolic fraction 
(20,000g for 10 minutes) from approximately 1 × 104 cells was incubated in a 
microtiter plate precoated with a primary antibody against histones, after 
which an HRP-conjugated secondary antibody against DNA was added. The 
relative level of DNA fragmentation was compared with that of the control that 
did not receive drug treatment. 
N. Extraction of Ceramides 
Cell pellets were re-suspended in 0.5 ml of PBS, and then added 3 ml 
of Methanol/chloroform (2:1) following the addition of 10 µl of 17:0 Ceramide 
(2.5 ng/l) as an internal standard. The samples were vortexed for 1 minute 
and incubated on ice for 10 minutes.  Chloroform (1 ml) and water (1.3 ml) 
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was added to separate the phases and samples were vortexed for 1 minute 
prior to centrifugation at 1,750g for 10 minutes at 10˚C.  The lower phase 
was transferred to a new glass tube. After evaporating the solvent under 
nitrogen at room temperature, the dried lipids were re-suspended respectively 
in 1 ml of MeOH for Mass spectrometry (MS) analyses.  
O. LC-ESI-MS/MS  
MS analyses were performed using API-4000 (Applied 
Biosystems/MDS SCIEX, Forster City, CA) with the Analyst data acquisition 
system. The instrument was equipped with a Z-spray ionization source. The 
nebulizer gas and desolvation gas were nitrogen and the collision gas was 
argon. Typical operating parameters were as follows: nebulizing gas (NEB) 15, 
curtain gas (CUR) 8, collision-activated dissociation (CAD) gas 35, 
electrospray voltage 4200, and temperature 500. Multiple reactions 
monitoring (MRM) mode was used for quantification. Negative monitoring 
ions were at m/z 550.4 (the parent ion)-294.2 (the product ion) for 17:0-CER, 
536.6-280.2 for 16:0-CER, 562.6-306.2 for 18:1-CER, 564.6-308.1 for 
18:0-CER,  592.6-336.2 for 20:0-CER, 646.7-390.2 for 24:1-CER and 
648.6-392.4 for 24:0-Cer. The dwell time in the MRM mode was 75 ms.  
Samples (10 µl each) were delivered into the electrospray ionization 
(ESI) source through a LC system (Agilent 1100) with an auto sampler.  The 
mobile phase was MeOH/water/AmOH (90:10:0.1, v/v/v).  
Standard curve for each ceramide were established for quantitative 
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analysis. Different concentrations (5-50 pg/l) of a particular form of ceramide 
were mixed with the same concentration (25 pg/l) of an internal standard 
17:0-Cer, and then performing ESI-MS analyses. The peak intensity ratios (a 
ceramide form/ internal standard) versus the concentration ratios (a ceramide 
form/ internal standard) were plotted and fitted to a linear regression.  
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III. Experimental Results 
A. Identification of FASN as an over-expressed protein in drug resistant 
MCF7/AdrVP3000 cells.  
SDS-PAGE analysis was used to compare protein profiles between 
the parental drug sensitive cell line MCF7 and its drug resistant derivative 
MCF7/AdrVp3000 cells. A protein of ~260 kDa was found to be 
over-expressed in the drug resistant MCF7/AdrVp3000 cells (Figure 3A). This 
protein was excised from the gel and subjected to analysis using 
matrix-assisted laser absorption/ionization-time-of-flight (MALDI-TOF) mass 
spectrometry. This protein was identified as human fatty acid synthase (FASN) 
by peptide matching/protein searching of the National Center of 
Biotechnology Information database using the ProFound search engine. The 
Z-score was 1.69 with peptide coverage of 5%.  
To verify that FASN is over-expressed in the drug resistant 
MCF7/AdrVp3000 cells, we first determined FASN expression level using 
Western blot. As shown in Figure 4, the FASN level in MCF7/AdrVp3000 cells 
is ~2 fold higher than that in the MCF7 cells. 
Since FASN is an enzyme, we next determined the FASN enzymatic 
activity in MCF7 and MCF7/AdrVp3000 cells to make sure that FASN is 
functional in MCF7 and drug-selected MCF7/AdrVp3000 cells. As shown in 
Figure 3B, the FASN activity in MCF7/AdrVp3000 cells was increased ~5 fold 
compared with that in MCF7 parental cells.  
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Figure 3. FASN is over-expressed in drug-resistant MCF7/AdrVp3000 
cells. A. SDS-PAGE profile of cell lysates of MCF7 and its drug-resistant 
derivative MCF7/AdrVp3000 cells. 20 µg of protein from MCF7 and 
MCF7/AdrVp3000 cells were separated by a 4% to 15% gradient precast 
SDS-PAGE and stained with Coomassie blue. ∗ indicates a high molecular 
weight protein (∼260 kDa) over-expressed in MCF7/AdrVp3000 cells, which 
was identified as FASN by mass spectrometry (access no. G01880). B. FASN 
activity in MCF7 and MCF7/AdrVp3000 cells. FASN activity was determined 
as described in Materials and Methods (n=5, p=0.0001).
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B. FASN expression level correlates with drug resistance in breast 
cancer cells.  
To determine whether the elevated FASN expression contributes to the 
drug resistance of MCF7/AdrVp3000 cells, we performed a correlative 
analysis of FASN expression with drug resistance. During the stepwise 
selection to generate MCF7/AdrVp3000 cells, two MCF7 derivatives, 
MCF7/AdrVp10 and MCF7/AdrVp100, with low and intermediate drug 
resistance levels were also generated (Chen et al., 1990; Lee et al., 1997; 
Litman et al., 2000). As shown in Figure 4A, the FASN protein level increased 
as the drug resistance level of the MCF7 derivative cells increased. The 
relative FASN expression level in MCF7 and its drug-selected derivatives 
were 1.0, 1.0, 1.4, 1.9, respectively.  
The mRNA level of FASN in MCF7 and its drug-selected derivatives 
was also assessed using real-time quantitative reverse transcription- PCR. As 
shown in Figure 4B, mRNA level of FASN dramatically increased in 
MCF7/AdrVp10 cells and was sustained in both MCF7/AdrVp100 and 
MCF7/AdrVp3000 cells.  The discordance between FASN mRNA level and 
protein expression suggests that the FASN expression may be regulated at 
the post-transcriptional level (Priolo et al., 2006).
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Figure 4.  (Legend on next page) 
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Figure 4. FASN expression level correlates with the drug resistance level 
in MCF7 and its drug-selected derivative cell lines. A. FASN expression in 
MCF7 and its stepwise-selected drug resistance derivative cell lines. 20 µg of 
protein, each from MCF7, MCF7/AdrVp10, MCF7/AdrVp3000, and 
MCF7/AdrVp3000 cells, were separated by SDS-PAGE followed by Western 
blot analysis using FASN antibody. GAPDH was used as a loading control. The 
relative level of FASN was determined by measuring the intensity of the FASN 
band compared with that of GAPDH band using software Scion Image. FASN 
expression levels in each cell line were normalized to that of MCF7. B. 
Real-time quantitative reverse transcription-PCR analysis of FASN mRNA level. 
Real-time quantitative reverse transcription-PCR was done by measuring the 
mRNA level using SYBR green and calculated in the fold change (2∆∆Ct) relative 
to MCF7 cells after normalization by internal control, GAPDH. 
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C. FASN overexpression leads to drug resistance in breast cancer cells. 
To determine if FASN overexpression is the cause of drug resistance 
or simply a result of drug selection, FASN expression in MCF7/AdrVp3000 
cells was knocked down using shRNA. A hairpin DNA segment targeting 
FASN was cloned into pRNA-U6.1/Neo vector (GeneScript, Piscataway, NJ) 
to constitutively express FASN siRNA. The FASN shRNA construct was then 
transfected into MCF7/AdrVp3000 cells and stable clones were selected 
using G418. As shown in Figure 5, the FASN protein level was decreased in 
two independent stable clones (Si18 and Si19) compared with the control 
clone (Scr) transfected with scrambled shRNA. The responses of these 
clones to various anticancer drugs were determined using the SRB 
cytotoxicity assay. The results showed that knock down of FASN expression 
significantly decreased the resistance level of MCF7/AdrVp3000 cells to both 
Adriamycin and mitoxantrone (Figure 6). Two other drugs, vinblastine and 
paclitaxel, were also tested. However, knocking down FASN expression in 
MCF7/AdrVp3000 cells did not affect the drug resistance level to these two 
drugs (data not shown).  
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Figure 5. Down-regulation of FASN expression in MCF7/AdrVp3000 cells 
using stable shRNA transfection. Drug resistant MCF7/AdrVp3000 cells 
were stably transfected with shRNA targeting FASN for silencing and 
scrambled shRNA as a control. 20 µg of protein each, from MCF7/AdrVp3000, 
MCF7/AdrVp3000 cells transfected with scramble shRNA control, and 2 
stable MCF7/AdrVp3000 clones with reduced FASN expression were 
separated with SDS-PAGE followed by Western blot analysis using FASN 
monoclonal antibody. GAPDH was used as a loading control. 
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Figure 6. (Legend on next page) 
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Figure 6. Down-regulation of FASN expression in MCF7/AdrVp3000 cells 
by stable shRNA transfection decreased their drug resistance. 
MCF7/AdrVp3000 cells were stably transfected with either sh-RNA 
specifically targeting FASN or control scrambled shRNA. Stable clones were 
tested for their resistance to various anticancer drugs by SRB cytotoxicity 
assay. Results were analyzed by GraphPad Prism (version 3.02).  A. A 
representative curve of those used to obtain IC50 value for Adriamycin, B. 
representative curve of those used to obtain IC50 value for mitoxantron, C. 
Summary of multiple experiments. Relative resistance factor = IC50 of 
FASN-shRNA transfected cells/IC50 of scrambled sh-RNA transfected cells. 
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       To further investigate the role of FASN in drug resistance, parental 
drug sensitive MCF7 cells were transfected with a plasmid containing FASN 
cDNA for ectopic overexpression. Stable clones were selected using G418 for 
analysis of FASN expression and drug resistance. As shown in Figure 7, two 
stable clones (F and F2) showed higher levels of FASN compared with the 
control vector-transfected MCF7 cells. As shown in Figure 8, the stable clones 
with FASN overexpression showed significantly higher resistance to several 
anti-cancer drugs including Adriamycin, mitoxantrone, cisplatin, camptothecin 
and etoposide than the vector-transfected MCF7 control cells. However, 
FASN overexpression did not change the drug resistance levels of FASN 
over-expressing MCF7 cells to vinblastine and paclitaxel (data not shown). 
Taken together, our data suggested that the increased FASN 
expression in MCF7/AdrVp3000 cells likely contributes to the drug resistance 
phenotype of this cell line. 
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Figure 7. Ectopic overexpression of FASN in MCF7 cells. Drug sensitive 
MCF7 cells were stably transfected with FASN cDNA for overexpression or 
transfected with empty vector as control. 20 µg of protein each, from MCF7, 
MCF7 cells transfected with vector control (M/Vec), and 2 stable MCF7 clones 
over-expressing FASN (M/F and M/F2) were separated by SDS-PAGE 
followed by Western blot analysis with FASN antibody. GAPDH was used as a 
loading control. 
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Figure 8. (Legend on next page)
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Figure 8. Increased FASN expression in MCF7 cells increased their 
resistance to various anticancer drugs.  MCF7 cells were stably 
transfected with either plasmid harboring FASN cDNA (F and F2) or empty 
vector (V). Stable clones were tested for their resistance to various anticancer 
drugs by SRB cytotoxicity assay. Results were analyzed by GraphPad Prism 
(version 3.02).  A-E, representative curves of those used to obtain IC50 
values for Adriamycin (A), mitoxantrone (B), Etoposide (C), Camptothecin (D), 
and Cisplatin (E). F, Summary of multiple experiments. Relative resistance 
factor = IC50 of FASN over-expressing cells/IC50 of vector-transfected control 
cells.  
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Orlistat is a U. S. Food and Drug Administration (FDA)-approved drug 
used for treating obesity. It works primarily on pancreatic and gastric lipase 
within the gastrointestinal (GI) tract (McNeely and Benfield, 1998). Orlistat 
was also found to be a rather selective FASN inhibitor targeting the 
thioesterase domain (Cheng et al., 2008; Kridel et al., 2004; Pemble et al., 
2007). Inhibition of FASN activity by Orlistat induces endoplastic reticulum 
stress and tumor cell death (Little et al., 2007), inhibits tumor growth, and 
prevents angiogenesis (Browne et al., 2006). 
As shown in Figure 6, reducing FASN expression can sensitize breast 
cancer cells to various anticancer drugs. We wanted to investigate whether 
Orlistat can also sensitize FASN over-expressing cancer cells. For this 
purpose, MCF7 stable clones with FASN overexpression were tested for their 
response to Adriamycin and mitoxantrone in the presence of 30 µM Orlistat. 
At this concentration, Orlistat has no toxicity to cells (data not shown). As 
shown in Figure 9, Orlistat was able to reverse FASN-mediated drug 
resistance in both MCF7 stable clones with FASN overexpression and the 
vector-transfected control cells, although the sensitization of 
vector-transfected cells by Orlistat is less than that of FASN over-expressing 
cells. MCF7 cells alone express low level of FASN, so it is not surprising to 
see the inhibitory effect of Orlistat in vector-transfected MCF7 cells. Thus, 
FASN inhibitors may be used as sensitizers in combination therapy of 
drug-resistant human breast cancers. 
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Figure 9. FASN inhibitor, Orlistat, can reverse FASN-mediated drug 
resistance. Two stable MCF7 clones with overexpression of FASN (M/F and 
M/F2) and a vector-transfected control (M/V) were treated with Adriamycin in 
the absence or presence of 30 µM Orlistat for 3 days followed by SRB 
cytotoxicity assay. Relative resistance factor=IC50 of Orlistat treated 
cells/IC50 of non-treated cells.
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       To determine if the FASN-mediated drug resistance is specific to 
MCF7 cells, siRNA specifically targeting FASN was transfected into another 
breast cancer cell line MDA-MB-468, which expresses high levels of 
endogenous FASN. As shown in Figure 10, decrease of FASN protein level in 
MDA-MB-468 cells by transient siRNA transfection persisted for at least 8 
days. The effect of FASN-knock-down on drug sensitivity of MDA-MB-468 
cells was next determined using the the SRB cytotoxicity assay. As shown in 
Figure 11, MDA-MB-468 cells transfected with FASN siRNA are significantly 
more sensitive to Adriamycin and mitoxantrone than the control cells 
transfected with scrambled siRNA. Thus, FASN overexpression-mediated 
drug resistance is not restricted to MCF7 cells. 
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Figure 10. Western blot analysis of FASN expression in MDA-MB-468 
cells. MDA-MB-468 cells were transiently transfected with either FASN siRNA 
(Si) or a negative control scrambled siRNA (Scr). Cells were collected at 
various days after transfection for Western blot analysis. 20 µg of protein from 
each set of transfected cells were separated with SDS-PAGE followed by 
Western blot analysis with FASN monoclonal antibody. GAPDH was used as 
a loading control. 
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Figure 11. (Legend on next page) 
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Figure 11. Decreased FASN expression can sensitize MDA-MB-468 cells 
to anticancer drugs. MDA-MB-468 cells were transiently transfected with 
either FASN siRNA (Si) or control scrambled siRNA (Scr). Cells were 
collected at different time post transfection and tested for their resistance to 
Adriamycin or mitoxantrone by SRB cytotoxicity assay. Results were analyzed 
by GraphPad Prism (version 3.02).  A. A representative curve of those used 
to obtain IC50 value for Adriamycin, B. A representative curve of those used to 
obtain IC50 value for mitoxantrone, C. Summary of multiple experiments. 
Relative resistance factor = IC50 of FASN-siRNA transfected cells/IC50 of 
scrambled si-RNA transfected cells. 
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       To determine if decreased FASN expression in non-cancerous 
mammary epithelial cells would decrease their sensitivity to anticancer drugs, 
similar knock-down experiments were performed using the human normal 
breast epithelial cell line MCF10A1. As shown in Figure 12A, FASN siRNA 
was able to knock-down FASN expression for at least 6 days post transfection. 
However, the sensitivity to Adriamycin and mitoxantrone of siRNA-transfected 
MCF10A1 cells exhibited no significant difference compared with the control 
cells transfected with scrambled siRNAs (Figure 12B). This observation is 
interesting and indicates that FASN may be used as a target for 
chemo-sensitization of breast cancer cells without affecting the drug 
sensitivity of normal mammary epithelial cells. 
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Figure 12. FASN silencing does not affect drug response of the normal 
breast epithelial cell line MCF10A1. A. MCF10A1 cells were transiently 
transfected with either FASN siRNA (Si) or a control scrambled siRNA (Scr). 
Cells were collected at various days after transfection for Western blot 
analysis of FASN expression. GAPDH was used as a loading control. B. 
MCF10A1 cells transfected with FASN siRNA or control scrambled siRNA 
were tested for their resistance to Adriamycin and mitoxantrone using SRB 
cytotoxicity assay. Relative resistance factor = IC50 of FASN-siRNA 
transfected cells/IC50 of scrambled si-RNA transfected cells.
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D. FASN overexpression does not affect intracellular drug accumulation.  
FASN overexpression in cancer cells affects membrane lipid 
composition, and thus possibly affects drug uptake through cell membrane or 
ABC transporter mediated drug efflux, both of which will decrease the 
intracellular drug accumulation. 
To determine if FASN expression level affects drug uptake through 
cell membrane, mitoxantrone accumulation was determined and compared 
between MCF7 cells with FASN overexpression and vector-transfected 
control cells using FACS analysis. As shown in Figure 13A, there is no 
difference in mitoxantrone accumulation between these cells. Thus, FASN 
overexpression likely does not affect drug uptake of mitoxantrone through cell 
membrane.   
To determine if FASN expression levels affect ABC 
transporter-mediated drug efflux, MCF7/AdrVp3000 cells, which are known to 
over-express several ABC transporters including ABCG2 (Liu et al., 2005), 
and its derivative stable clones with reduced FASN expression were tested for 
their ability to accumulate mitoxantrone. As shown in Figure 13B, 
knocking-down FASN expression in MCF7/AdrVp3000 cells did not affect 
mitoxantrone accumulation, indicating that FASN expression did not affect the 
efflux activity of ABC transporters in these cells. We also found that FASN 
overexpression did not affect sensitivity of cells to paclitaxel and vinblastine, 
substrates of multidrug-resistant ABC transporters. This finding further 
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confirmed our conclusion that FASN expression does not affect ABC 
transporter activity. 
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Figure 13. FASN expression levels do not affect intracellular drug 
accumulation. Vector transfected MCF7 (Vec) and two FASN 
over-expressing stable clones (F and F2) (A) and MCF7/AdrVp3000 cell line 
transfected with scrambled siRNA (Scr) and two derivative clones with 
down-regulated FASN expression (si18 and Si19)  (B) were tested for their 
ability to accumulate anticancer drug mitoxantrone using FACS analysis. 
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E. FASN overexpression does not affect cell proliferation.  
Another possible mechanism of FASN-mediated drug resistance is 
that FASN expression may affect cell proliferation. To test this possibility, the 
cell growth rate was compared among FASN over-expressing MCF7-derived 
stable cell clones, as well as in FASN knock-down MCF7/AdrVp3000 clones 
and the vector-transfected control cell line. As shown in Figure 14, 
overexpression or decreasing FASN expression does not affect the growth 
rate of these cells. Therefore, the drug responses mediated by FASN 
overexpression is unlikely due to its effect on cell proliferation. 
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Figure 14. FASN expression levels have no effect on cell proliferation. 
Vector transfected MCF7 (Vec) and its two FASN over-expressing stable 
clones (F and F2) (A) and MCF7/AdrVp3000 cell line transfected with 
scrambled siRNA (Scr) and its two derivative stable clones with 
down-regulated FASN expression (si18 and si19) (B) were determined for 
their cell growth rate over a period of two weeks. Cell density was determined 
by crystal violet staining.
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F. FASN overexpression protects cancer cells from drug-induced 
apoptosis. 
Many anticancer drugs, such as Adriamycin, cause apoptosis in 
cancer cells. To determine if the overexpression of FASN protects cancer cells 
from drug-induced apoptosis, Poly ADP-Ribose Polymerase (PARP) cleavage 
was analyzed. PARP is a 116 kDa protein whose cleavage serves as a marker 
of cells undergoing apoptosis (Oliver et al., 1998). PARP cleavage by 
caspases during apoptosis generates two fragments, the PARP 
amino-terminal DNA binding domain (24 kDa) and the carboxy-terminal 
catalytic domain (89 kDa) (Lazebnik et al., 1994; Nicholson et al., 1995). As 
shown in Figure 15A, the 89-kDa PARP cleavage product was produced in 
both FASN over-expressing MCF7 cells and control cells following treatment 
with 1 µM Adriamycin for 48 hours. However, in the two stable MCF7 clones 
which over-express FASN, the drug-induced PARP cleavage was much lower. 
Adriamycin induced apoptosis was also quantified by the level of DNA 
fragmentation using Cell Death Detection ELISA (Roche, Indianapolis, IN). As 
shown in Figure 15B, FASN over-expressing MCF7 cells showed a 
significantly lower level of DNA fragmentation compared with control cells. 
Together, these results indicate that MCF7 cells with FASN overexpression 
are more resistant to drug-induced apoptosis.   
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Figure 15. (Legend on next page) 
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Figure 15. FASN overexpression protects MCF7 cells from drug induced 
apoptosis.  Two stable MCF7 clones with FASN overexpression (F and F2) 
and a control clone transfected with empty vector (V) were treated with 1µM of 
Adriamycin for 48 hours, A. PARP cleavage was analyzed using a Western 
blot. GADPH was used as a loading control.  B. Apoptosis at 48 hours after 
Adriamycin treatment was estimated by DNA fragmentation ELISA. 
Enrichment factor= Absorbance of cells treated with Adriamycin/absorbance 
of corresponding cells without Adriamycin treatment.
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G. FASN overexpression inhibits caspase-8 activation, and thus 
apoptosis. 
After anti-cancer drug treatment, apoptosis occurs in cancer cells 
through two distinctive pathways, the mitochondrial pathway followed by 
activation of Caspase-9, or cell death receptor pathway followed by activation 
of Caspase-8. To determine which pathway is affected by FASN 
oeve-rexpression, cells were treated with 1 µM of Adriamycin for 48 hours. 
Cleavage of Caspase-8 and Caspase-9 to their corresponding active forms 
was determined using Western blot analysis. As shown in Figure 16, 
Caspase-9 failed to be activated in both FASN over-expressing clones and 
vector-transfected control cells after Adriamycin treatment. However, 
Caspase-8 activation was much higher in vector-transfected control cells, 
compared with FASN over-expressing clones. These results suggest that 
FASN overexpression likely blocks the drug-induced activation of caspase-8, 
and subsequently apoptosis.  
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Figure 16. (Legend on next page)
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Figure 16. FASN overexpression in MCF7 cells blocks the activation of 
caspase-8, but not caspase-9. Two stable MCF7 clones with FASN 
overexpression (F and F2) and a control clone transfected with vector (V) 
were plated at 3×106 cells/plate on 10cm plates for 24 hours and then treated 
with 1 µM of Adriamycin for 48 hours followed by analysis of caspase-8 and 
caspase-9 cleavage using a Western blot. Actin was used as a loading 
control. 
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Caspase-8 exists in cells as a pro-caspase. After drug treatment, 
pro-caspase-8 is recruited to death-inducing signal complex (DISC) and 
activated to initiate a cascade of proteolytic events resulting in apoptosis. The 
lack of caspase-8 activation in FASN over-expressing clones suggested a 
possible binding of caspase-8 by an inhibitor even under drug treatment 
conditions.  
One of the possible ways to inhibit caspase-8 activation is that FASN 
binds to caspase-8 as an inhibitor. Therefore, in FASN over-expressing clones, 
more caspase-8 is sequestered by binding to FASN, and less caspase-8 is 
available to be activated. To rule out this possibility, however, 
co-immunoprecipitation was used to determine if FASN and caspase-8 can be 
found in association. Cell lysates from FAS over-expressing MCF7 cells and 
vector-transfected control cells were first subjected to immunoprecipitation 
with mouse anti-caspase 8 monoclonal antibody, followed by Western blot 
analysis using mouse anti-FASN monoclonal antibody. As shown in Figure 17, 
FASN and caspase-8 did not co-immunoprecipitate, indicating that they do not 
bind to each other. Furthermore, examination of FASN sequence did not show 
any caspase-8 binding motif in the FASN protein, confirming that FASN likely 
does not bind to caspase-8. 
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Figure 17. FASN does not bind caspase-8 in MCF7 cells. 200 µg cell 
lysates from two MCF7 stable clones over-expressing FASN (F and F2) and 
vector-transfected control (Vec) were immunoprecipitated with anti-caspase-8 
monoclonal antibody followed by Western blot (I.B) analysis with either 
caspase-8 monoclonal antibody or FASN monoclonal antibody.  
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c-FLIP is a well known caspase-8 inhibitor, it degrades after drug 
treatment to release caspase-8 for activation of apoptosis. There are two 
forms of c-FLIP, FLIPs and FLIPL. FLIPs has been shown to inhibit apoptosis, 
yet FLIPL has both pro- and anti-apoptotic activities depending on its 
expression level (Kataoka, 2005). To determine if FASN overexpression 
blocks c-FLIP degradation after drug treatment, c-FLIP expression level in 
FASN over-expressing MCF7 and vector-transfected control cells was 
compared by Western blot analysis. As shown in Figure 18, both c-FLIPL and 
c-FLIPs protein levels were similar in FASN over-expressing clones compared 
with vector-transfected cells. After Adrimaycin treatment, c-FLIPL was totally 
degraded, and a smaller size (~43 kDa) product was generated. However the 
level of this smaller product showed no differences between FASN 
over-expressing clones and vector-transfected controls at any time points. 
Similarly, c-FLIPs was also degraded or down-regulated after drug treatment, 
although to a lesser extent compared with c-FLIPL. Again no difference was 
found in the level of c-FLIPs in FASN over-expressing clones compared with 
vector-transfected controls at any time points after Adriamycin treatment. 
These results indicate that FASN overexpression does not inhibit caspase-8 
activation through modulating c-FLIP, but may affect upstream signals that 
activate caspase-8. 
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Figure 18. FASN overexpression does not affect expression or 
degradation of c-FILPL and C-FLIPs. A. Western blot analysis of c-FLIP 
expression in MCF7 cells with FASN overexpression (F and F2) and 
vector-transfected control cells (V), B. Two stable MCF7 clones with FASN 
overexpression (F and F2) and a control clone transfected with vector (V) 
were treated with 1 µM of Adriamycin for up to 72 hours followed by analysis 
of c-FLIP expression using a Western blot. GAPDH was used as a loading 
control. 
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H. FASN overexpression decreases Adriamycin-induced ceramide 
generation.  
Because FASN overexpression likely increases the production of 
palmitate, it is possible that increasing cellular plamitate level would increase 
the level of drug resistance. To test this hypothesis, MCF7 cells were treated 
with or without palmitate and tested for their responses to Adriamycin and 
mitoxantrone using the SRB cytotoxicity assay. As shown in Figure 19, the 
palmitate-treated cells were significantly more resistant to both Adriamycin 
and mitoxantrone compared to the vehicle-treated control cells. However, the 
degree of increase in resistance is less than that induced by FASN 
overexpression (0.3-0.4 fold increase compared to 2-3 fold increase). This 
limited increase in resistance by palmitate may be due to the difficulties in 
delivering palmitate into cells. 
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Figure 19. Supplementation of palmitate to MCF7 cells increases their 
resistance to anticancer drug treatment. MCF7 cells were first treated with 
100 µM of palmitic acid (PA) for 24 hours followed by treatment with 
Adriamycin (A) or mitoxantrone (B) and subjected to a SRB cytotoxicity assay. 
Relative resistance factor = IC50 of palmitate treated cells/IC50 of non-treated 
cells. 
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Palmitate is the precursor of many other lipids in cells, the above 
observation that palmitate supplementation increase MCF7 cells’ resistance 
to anticancer drug treatment implies that FASN overexpression likely affects 
the production of cellular lipids that involve in cell survival, proliferation and/or 
apoptosis. 
One way by which Adriamycin induces apoptosis in cancer cells is to 
increase ceramide generation (Senchenkov et al., 2001). Inhibition of FASN 
expression in MCF7 cells has been shown to increase ceramide level 
(Bandyopadhyay et al., 2006). Based on these observations, I hypothesized 
that FASN overexpression may decrease Adriamycin-induced ceramide 
production. To test this hypothesis, amount of ceramide was measured using 
mass spectrometry in two FASN over-expressing MCF7 clones and 
vector-transfected control cells at different time point after 1 µM of Adriamycin 
treatment.  As shown in Figure 20, ceramide level increased in both FASN 
over-expressing MCF7 clones and vector-transfected control at a 
time-dependent manner. At 48 hours after Adriamycin treatment, the level of 
ceramide in the FASN over-expressing clones was significantly lower 
compared with that of vector-transfected cells. This result indicates  that 
FASN overexpression in MCF7 cells inhibits the Adriamycin-induced ceramide 
generation, and thus apoptosis. 
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Figure 20. FASN overexpression inhibits Adriamycin-induced ceramide 
generation. FASN over-expressing MCF7 cells and the vector-transfected 
control cells were treated with 1 µM of Adriamycin for different time and the 
level of ceramide in cells was measured using mass spectrometry. Relative 
ceramide level = amount of ceramide at different time point after Adriamycin 
treatment/ amount of ceramide at 0 hours. 
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I. FASN overexpression increases the level of AKT activation in MCF7 
cell lines.  
There are several reports about the positive feedback relationship 
between FASN and activation of Akt (Orita et al., 2008; Uddin et al., 2008; 
Wang et al., 2005). To determine if the FASN overexpression in our stable 
MCF7 clones may increase the activation of AKT compared with 
vector-transfected control cells, Western blot analysis was performed to 
compare the phosphorylated-AKT level in two MCF7 stable clones with FASN 
overexpression with vector-transfected control MCF7 cells. Cells were 
cultured under serum free condition for 24 hours and then serum was added 
for 30min before collecting cells for cell lysate preparation. As shown in Figure 
21, the phosphorylated-AKT level was higher in two FASN over-expressing 
clones compared with vector-transfected control. This result suggested that 
there is a positive feedback between FASN overexpression and AKT 
activation in MCF7 cells.  
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Figure 21. FASN overexpression increases the activation of AKT in 
MCF7 cells after serum stimulation. Two FASN over-expressing MCF7 
clones (F and F2) and vector-transfected control (V) were cultured with serum 
free DMEM for 24 hours before addition of serum for 30 min. Cells were then 
collected for analysis of phosphorylated AKT level using Western blot. 
GAPDH was used as loading control.
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J. Activation of AKT does not contribute to increased drug resistance in 
FASN over-expressing MCF7 cells.  
AKT activation promotes cell survival and enhances tumor cell growth 
and invasiveness. Moreover, active AKT has been shown to confer resistance 
to chemotherapy and radiation in cell lines derived from a variety of tumor 
type (Datta et al., 1999; Page et al., 2000; Testa and Bellacosa, 2001). It has 
been shown that in MCF7 cells, Adriamycin increased PI3K dependent AKT 
phosphorylation as early as 1hr after treatment with a peak at 24 hours. This 
increase in AKT activation may contribute to the resistance of MCF7 cells to 
Adriamycin (Li et al., 2005). PI3K/AKT activation occurs at the plasma 
membrane and FASN overexpression has been shown to alter membrane 
lipid composition specifically within the membrane raft domains, where many 
signaling molecules reside.  Based on the above knowledge, we 
hypothesized that FASN overexpression in MCF7 cells may increase the level 
and/or prolong the duration of AKT activation after Adriamycin treatment. To 
test this hypothesis, phophorylated-AKT levels were determined using 
Western blot in two stable MCF7 clones with FASN overexpression compared 
with vector-transfected cells at different times following Adriamycin treatment. 
As shown in Figure 22, phosphorylated-AKT levels gradually increased within 
24 hours and started to decrease after 48 hours of 1µM Adriamycin treatment. 
However, the level of phosphorylated-AKT in FASN over-expressing clones 
was not higher than that of vector-transfected control cells.   
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Figure 22. FASN overexpression does not affect Adriamycin-induced 
phosphorylation of Akt in MCF7 cells. Two stable MCF7 clones with FASN 
overexpression (F and F2) and a control clone transfected with empty vector 
(V) were treated with 1µM of Adriamycin for up to 48 hours followed by 
analysis of phopsphorylated-Akt (p-AKT) and total-Akt (t-AKT) using Western 
blot analysis.
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       To further confirm the effect of AKT activation on FASN induced drug 
resistance, MCF7 cells were transiently transfected with siRNA specifically 
targeting FASN or scrambled siRNA as control. As shown in Figure 23, FASN 
expression levels were successfully decreased in MCF7 cells. The effect of 
FASN knock-down on Adriamycin-induced phosphorylated-AKT levels were 
determined by Western blot analysis. As shown in Figure 23, the 
phosphorylated-AKT levels were not lower in FASN siRNA transfected MCF7 
cells compared with scrambled siRNA trasfected control cells, regardless of 
the concentration of Adriamycin used or duration of treatment. 
Together, these results indicated that activation of AKT in FASN 
over-expressing MCF7 cells does not contribute to their higher resistance to 
various anticancer drugs. 
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Figure 23. Decreased FASN expression does not affect 
Adriamycin-induced AKT activation in MCF7 cells. MCF7 cells were 
transfected with either siRNA specifically targeting FASN (Si) or scrambled 
siRNA (Scr) as control. 48 hours after transfection, cells were treated with 
different concentrations of Adriamycin for the indicated time. The level of 
FASN, cleaved PARP, phosphorylated-AKT and total AKT was determined 
using Western blot analysis.  
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IV. Discussion 
Increased lipogenesis in tumor tissues was found as early as the 
1950s (Medes et al., 1953), and by the mid-1980, Baker and colleagues found 
that endogenous fatty acid synthesis provides a major source of fatty acids for 
the growth of tumor cells (Ookhtens et al., 1984). However, the fatty acid 
synthesis pathway did not become a focus of interest until 1994, when 
Kuhjada and colleagues identified the oncogenic antigen-519 (OA-519), a 
molecule found in tumor cells from breast cancer patients with a markedly 
poorer prognosis, as fatty acid synthase (FASN) (Kuhajda et al., 1994). It 
gradually became clear that FASN expression is high in a biologically 
aggressive subset of human carcinomas, including breast cancers (Kuhajda, 
2000; Kuhajda, 2006; Menendez and Lupu, 2007). FASN overexpression and 
hyperactivity were also found to correlate with poor prognosis (Kuhajda, 2000; 
Kuhajda, 2006; Menendez and Lupu, 2007). In this study, we demonstrated 
FASN overexpression as a new mechanism of drug resistance in a series of 
Adriamycin-selected MCF7 breast cancer cell lines. We propose that one of 
the mechanisms of FASN-induced drug resistance is that FASN 
overexpression protects cancer cells from drug-induced apoptosis by blocking 
the activation of caspase-8. FASN-mediated drug resistance is not specific to 
MCF7 cells. More interestingly, inhibition of FASN expression in normal breast 
epithelial cells does not affect their drug responsiveness, suggesting that 
FASN can be used as a target for developing chemosensitizing agents in 
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combinational therapy without affecting normal cells. The above observations 
strongly suggest that overexpression of FASN in breast cancer cells likely 
plays an important role in drug resistance and thus poor prognosis of breast 
cancer patients. Inhibition of FASN, by inhibitors or siRNA specifically 
targeting FASN, preferentially induces tumor cell apoptosis and retards tumor 
growth in xenograft models (Bandyopadhyay et al., 2006; Baron et al., 2004; 
Browne et al., 2006; Gao et al., 2006; Kridel et al., 2004; Kuhajda et al., 2000; 
Li et al., 2001; Little et al., 2007; Menendez et al., 2004c; Menendez et al., 
2004d; Menendez et al., 2005d; Menendez et al., 2005e; Menendez et al., 
2004e; Pan et al., 2007; Pizer et al., 1998; Pizer et al., 1996a; Thupari et al., 
2001; Vazquez-Martin et al., 2007a; Wang et al., 2005; Yeh et al., 2003; Zhou 
et al., 2007; Zhou et al., 2003). Thus, FASN is now considered a potential 
target for anti-cancer therapy. 
In normal cells, FASN expression is under tight control by nutritional 
signals in liver and adipose tissues and hormonal signals in lactating breast 
and cycling endometrium (Kuhajda, 2000). However, in cancer cells, FASN 
overexpression is thought to be the result of inappropriate activation of growth 
factors receptors such as epidermal growth factor receptor, keratinocyte 
growth factor receptor, and HER-2 receptor tyrosine kinase (Kumar-Sinha et 
al., 2003; Menendez et al., 2004d; Oskouian, 2000; Swinnen et al., 2000; 
Yoon et al., 2007; Zhang et al., 2005). These growth factors activate 
downstream signaling pathways, particularly the PI3K/Akt pathway, to 
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stimulate transcriptional upregulation of FASN through activation of 
SREBP-1c (Ettinger et al., 2004; Furuta et al., 2008; Porstmann et al., 2005; 
Swinnen et al., 2000; Yang et al., 2002b; Yang et al., 2003). Also, in prostate 
cancer cells, FASN protein was shown to be stabilized by USP2a, an 
ubiquitin-specific protease (Priolo et al., 2006). However, the mechanism for 
further up-regulation of FASN in drug-resistant cancer cells, compared with 
their parental sensitive ones, remains to be determined. In this study, I show 
that both mRNA and protein levels of FASN increase in drug-selected 
MCF7/Adr cell lines compared with drug sensitive MCF7 parental cells. 
However, there is an obvious discordance in the mRNA and protein 
expression level of FASN in the drug-selected MCF7 cells lines. The mRNA 
level increased very early in the drug selection process in MCF7/AdrVp10 
cells, while the protein level is similar to that of MCF7 cells. Protein levels 
started to increase later in MCF7/AdrVp100 cells, with the mRNA level of FAS 
remaining steady. It is reasonable to conclude that in drug resistant MCF7 cell 
lines, FASN expression is controlled not only at the transcriptional level, but 
also at the post-transcriptional level, including the regulation of translation 
and/or protein stability. Moreover, increased FASN expression in the early 
stepwise-selected breast cancer cell lines suggests that FASN may be an 
early response gene for drug insult. 
Overexpression of FASN in MCF7 cells increased their drug 
resistance to a broad range of anti-cancer drugs such as Adriamycin, 
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mitoxantrone, etoposide, camptothecin and cisplatin, but did not affect the 
drug resistance levels to vinblastine and paclitaxel. Adriamycin and 
mitoxantrone are anthracyclines which act as DNA intercalators, and 
inhibitors of topoisomerase II. Etoposide is a classic topoisomerase II inhibitor, 
Camptothecin is a topoisomerase I inhibitor, while cisplatin is a DNA 
alkylating-mimetic agent which can produces intra-stand DNA crosslink. All of 
the above drugs can produce DNA strand breaks that lead to cancer cell 
apoptosis through the activation of caspase-8. In this study, we showed that 
FASN overexpression blocks the activation of caspase-8 in FASN 
over-expressing MCF7 cells, which helps to explain the increased resistance 
to these drugs seen in the FASN over-expressing cells. Vinblastine inhibits 
the assembly of microtubules and paclitaxel interferes with normal 
microtubule breakdown, thus blocking cells in mitosis. FASN overexpression 
did not increase resistance to these two drugs. Further investigation of the 
apoptotic mechanisms of these drugs will help to better define how FASN 
contributes to the increased drug resistance phenotype in cancer cells.               
Inhibition of FASN expression using siRNA or inhibition of FASN 
activity by inhibitors C75 or cerulinin have been reported to cause apoptosis in 
a variety of cancer cell lines (Bandyopadhyay et al., 2006; Baron et al., 2004; 
Browne et al., 2006; De Schrijver et al., 2003; Gao et al., 2006; Horiguchi et 
al., 2008; Knowles et al., 2004; Kridel et al., 2004; Li et al., 2001; Little et al., 
2007; Menendez et al., 2004c; Menendez et al., 2004d; Menendez et al., 
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2004e; Pizer et al., 1998; Thupari et al., 2001; Wang et al., 2005; Zhou et al., 
2003). Interestingly, we did not observe apoptosis of drug-resistant breast 
cancer cells following reduction of FASN expression using shRNA. The 
reason for the difference between these studies is currently unknown. One 
possibility is that FASN expression in drug resistant cells was so high that the 
reduction of FASN expression in the drug-resistant cells was insufficient to 
induce apoptosis as observed in the previous studies using non-drug-selected 
cancer cell lines. Another reason is that during the selection of stable clones 
with FASN down-regulation, clones which could undergo apoptosis can 
happen were eliminated during the selection procedure.   
The mechanism of FASN-mediated drug resistance is not yet 
understood. There are several possible ways that FASN may affect cancer 
cell responsiveness to drugs.  
First, the newly synthesized fatty acids by FASN in cancer cells are 
saturated and mono-unsaturated. In cancer cells, these fatty acids are mainly 
incorporated into cellular membrane. Therefore, the increased lipid synthesis 
in cancer cells may not only increase the quantity of lipids in cell membranes 
required for cell growth but also change the lipid composition of the 
membrane. In fact, Rakheja and colleagues showed that there is an increased 
ratio of saturated to unsaturated C18 fatty acids in colonic adenocarcinoma 
with high levels of FASN expression (Rakheja et al., 2005; Swinnen et al., 
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2003). These changes in membrane composition may result in a decrease in 
the membrane permeability to anticancer drugs so that the intracellular drug 
concentration is below the effective therapeutic levels, which in turn causes 
drug resistance. The changes in membrane composition may also enhance 
the activity of membrane drug efflux pumps, such as ABCG2, which actively 
pumps out anticancer drugs and hence effectively reduces intracellular drug 
concentration. However, we have ruled out these possibilities. It is also 
unlikely that ABCG2 plays any role in FASN-mediated drug resistance 
because knocking down FASN expression in MDA-MB-468 cells or 
over-expressing FASN in MCF7 cells changed the drug response level of 
these cells, whereas they don’t express any detectable level of ABCG2.  
Second, FASN has been suggested to promote cancer cell 
proliferation (Browne et al., 2006; Kuhajda, 2006). It is possible that FASN 
overexpression affects cell growth rate or cell cycle distribution, which in turn 
decreases the cellular responses to anticancer drugs. However, we showed 
that changing the FASN expression level did not change the cell proliferation 
rate under normal growth conditions. Hence, the change in cell proliferation or 
cell cycle distribution due to FASN overexpression is not likely the reason for 
FASN-mediated drug resistance. Menendez and colleagues recently showed 
that enforced overexpression of FASN in HBL100 and NIH-3T3 cells 
significantly increased cell proliferation under low-serum (0.1% FBS) 
conditions, suggesting that increased FASN expression may increase the 
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proliferative potential of the cells (Vazquez-Martin et al., 2008). It is intriguing 
to test whether the FASN over-expressing MCF7 cells changes their growth 
speed under low serum conditions. 
Third, most anticancer drugs exert their effect by inducing apoptosis 
in cancer cells. There are two distinctive apoptotic pathways, the mitochondria 
pathway with subsequent activation of caspase-9, or cell death receptor 
pathway, and alternatively activation of caspase-8. Our results indicated that 
FASN overexpression blocks the activation of capase-8. Caspase-8 exists as 
a pro-caspase and binds to its inhibitor, c-FLIP, under normal condition. After 
drug treatment, c-FLIP is degraded and caspase-8 is then cleaved to an 
active form, initiating a cascade of proteolytic events resulting in apoptosis 
(Kataoka, 2005). However, FASN overexpression did not change the 
expression level or degradation of c-FLIP after drug treatment. These results 
suggested that FASN overexpression does not affect the caspase-8 inhibitor, 
c-FLIP, but affects either the upstream signals that activate caspase-8 or the 
formation of death-inducing signaling complex (DISC). Recent studies 
suggest that lipid rafts serve as the plasma membrane platforms for 
death-receptor initiated signaling (Muppidi et al., 2004). FASN expression has 
been shown to affect the composition of lipid rafts (Swinnen et al., 2003). It is 
very likely that FASN overexpression in MCF7 cells affects the formation of 
DISC and subsequently downstream signaling (Song et al., 2007). 
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Supplementation of palmitate, the precursor for the synthesis of many 
lipid molecules, to MCF7 cells significantly increased their drug resistance. 
The level of drug resistance in palmitate-treated MCF7 cells, however, is not 
as substantial as seen in FASN over-expressing MCF7 cell line, which may be 
due to the difficulty of delivering long chain fatty acids into cells. Palmitate is 
synthesized by FASN using malonyl-CoA and acetyl-CoA in the presence of 
NADPH. FASN overexpression and hyperactivity will thus increase the 
production of palmitate. Previous results from other groups have shown that 
supplementation of palmitate can rescue FASN knockdown-induced 
apoptosis, suggesting a critical role of palmitate or its metabolic derivatives in 
the survival of breast cancer cells (Chajes et al., 2006). Clinically, dietary 
saturated palmitic acid was associated with an increased risk of breast cancer 
(Chajes et al., 1999; Saadatian-Elahi et al., 2002). The de novo synthesized 
fatty acids in cancer cells are mostly incorporated into cellular membranes, 
especially lipid raft aggregates (Swinnen et al., 2003), where many cellular 
signaling events initiate. In breast cancers, the fatty acid composition of cell 
membrane is significantly altered compared with the surrounding healthy 
tissues (Chajes et al., 1995). Such an alteration could have profound effects 
on many cellular processes including initiation of cellular signaling events 
such as growth factor signaling, biosynthesis of signaling lipids, and 
maintenance of mitochondrial membrane potential, etc. Another interesting 
aspect of cellular palmitate is that palmitate is an allosteric inhibitor of fatty 
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acid synthesis in lactating mammary gland. Yet in breast cancer cells, it is 
obvious that this feedback inhibitory effect of palmitate is deficient.  
Over-production of palmitate in FASN over-expressing MCF7 cells 
may affect the biosynthesis of signaling lipids that involve in cell survival, 
proliferation, and/or apoptosis. Knocking down FASN expression in MCF7 
breast cancer cells using siRNA significantly increased the synthesis of 
ceramide and up-regulated the expression of several pro-apoptotic genes, 
such as BNIP3, TRAIL, and DAPK2 (Bandyopadhyay et al., 2006). It is thus 
tempting to propose that FASN overexpression in drug-resistant cells causes 
decreased expression of these proapoptotic genes and ceramide levels, 
which in turn causes drug resistance. It has been shown that Adriamycin 
induces apoptosis in cancer cells by generating ceramide from sphingomyelin 
breakdown or de novo synthesis (Bollinger et al., 2005; Reynolds et al., 2004). 
Results from current study showed that the increased FASN expression level 
in drug-resistant cells decreased the level of Adriamycin-induced ceremide, 
thus may protect cancer cells from drug-induced apoptosis.  
On one hand, FASN overexpression blocks the apoptotic signals 
generated after anti-cancer drug treatment. On the other hand, it may also 
activate cellular survival pathways, such as PI3K/Akt pathway, to promote cell 
survival after drug insult. In this study, I showed that elevated FASN 
expression in MCF7 cells increased the serum-stimulated phosphorylated-Akt 
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levels as predicted based on previous research results (Wang et al., 2005). 
However, increased active Akt levels did not have any protection against 
Adriamycin induced apoptosis since level of active Akt in FASN 
over-expressing clones showed no higher level compared with 
vector-transfected control cells after Adriamycin treatment. 
As I and others have shown, decreasing FASN expression or 
inhibiting its activity, sensitizes the drug-resistant cancer cells to traditional 
anticancer drugs (Menendez et al., 2004a; Menendez et al., 2005c; 
Menendez et al., 2005e; Menendez et al., 2006b). These observations 
suggest that FASN inhibitor may be used in combination therapy. The fact 
that inhibition of FASN expression in normal breast epithelial cells does not 
affect their drug responsiveness further supports the above idea. One 
concern is that inhibiting FASN may affect bone marrow or other critical 
normal cells, thus limiting the use of FASN inhibitors. However, a study using 
FASN inhibitor cerulenin or C75 on diet-induced obese mice showed that 
FASN inhibitors substantially decreased fatty liver and adipose mass without 
hepatocellular injury or fat necrosis (Loftus et al., 2000). Another study using a 
novel FASN inhibitor Orlistat in a prostate cancer xenograft model with PC-3 
cells showed that Orlistat prevented the growth of PC-3 tumors, while mice 
exhibited no outward signs of toxicity, experienced no loss of weight, nor were 
there any effects of Orlistat on hematocrit or white blood cell levels (Kridel et 
al., 2004). These data imply that targeting FASN may not have significant side 
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effect on normal cells. Orlistat is a US Food and Drug 
Administration–approved drug for treating obese patients (McNeely and 
Benfield, 1998).  It has also found to be an inhibitor of FASN (Kridel et al., 
2004). Recent co-crystalization study of Orlistat and the FASN thioesterase 
domain further confirmed the inhibitory effect of Orlistat on FASN (Pemble et 
al., 2007). Orlistat induces endoplasmic reticulum stress and tumor cell death, 
inhibits tumor growth and prevents angiogenesis (Browne et al., 2006; Little et 
al., 2007). In this study, we showed that Orlistat can sensitize FASN 
over-expressing MCF7 cells to various anticancer drugs. Even though Orlistat 
has low oral bioavailability, and it is rapidly degraded after i.v. injection (Kridel 
et al., 2004), it provides a starting backbone for the design of new compounds 
as sensitizers in combination therapy for cancers.  
Based on the results from this study, I proposed a model of 
FASN-induced drug resistance (Figure 24). In cancer cells, anticancer drugs 
such as Adriamycin induce ceramide production either through de novo 
synthesis or breakdown of sphigomyelin (Bollinger et al., 2005; Reynolds et 
al., 2004; Senchenkov et al., 2001). Increased ceramide leads to activation of 
caspase-8 and then apoptosis. On the other hand, Adriamycin can also 
induce the production of diacylglycerol (DAG) by breakdown of phospholipids 
via phospholipases (Bettaieb et al., 1999). DAG is a lipid second messenger 
that promotes cell survival. DAG also inhibits sphingomyelinase (SMase), 
thus inhibit ceramide generation through sphigomyelin breakdown (Hannun 
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and Obeid, 1995). Ceramide and DAG counterbalance in cells to determine 
cell survival or apoptosis. In drug sensitive cells, Adriamycin-induced 
ceramide production overpowers DAG production, so cells go to apoptosis. 
However, in FASN over-expressing cancer cells, palmitate production 
increased. And since palmitate is incorporated into membrane phospholipids, 
phospholipids level goes up, and Adriamycin-induced DAG generation will 
increase. This Increase in DAG generation inhibits ceramide production by 
inhibiting SMase, resulting in the inhibition of the downstream caspase-8 
activation and apoptosis. In this case, survival signals overpower the 
apoptotic signals and cells with FASN overexpression can survive the 
chemotherapy. Clearly, further experiments are needed to test this 
hypothesis. 
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Figure 24. Mechanism of FASN-mediated drug resistance. Adriamycin 
induces generation of both ceramide and diacylglycerol (DAG), which 
counterbalance each other to decide the fate of the cells after drug treatment. 
In FASN over-expressing cells, generation of DAG and downstream survival 
signals overpower the generation of ceramide induced apoptotic signals, thus 
cells with FASN overexpression become resistant to chemotherapy. 
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V. Summary and Conclusion 
The experimental results of this dissertation can be summarized as 
follows: 
1. The level of drug resistance in the drug-selected MCF7 cell lines 
correlates with the level of FASN expression. 
2. Down-regulation of FASN expression in the drug resistant 
MCF7/AdrVp3000 cells reverses Adriamycin and mitoxantrone resistance 
phenotype. 
3. Ectopic overexpression of FASN in the parental drug sensitive 
MCF7 cells increases resistance to Adriamycin, mitoxantrone, etoposide, 
camptothecin, and cisplatin. 
4. FASN overexpression does not alter the sensitivity to vinblastine 
and paclitaxel in MCF7 and MCF7/AdrVp3000 cell lines with altered FASN 
expression. 
5. Down-regulation of FASN expression in the breast cancer cell line 
MDA-MB-468 decreases the drug resistance level to Adriamycin and 
mitoxantrone.  
6. Down-regulation of FASN expression levels in the normal breast 
epithelial cell line MCF10A1 does not alter its drug resistance level.  
7. FASN overexpression does not affect drug uptake or membrane 
transporter activity in MCF7 and drug-selected MCF7/AdrVp3000 cells. 
8. FASN overexpression does not affect cancer cell proliferation 
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under normal growth conditions.  
9. FASN overexpression protects cancer cells from drug-induced 
apoptosis by blocking the drug-induced caspase-8 activation. 
10. FASN overexpression likely causes increased palmitate 
production. 
11. FASN overexpression decreases Adriamycin-induced ceramide 
production. 
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VI. Future Plans 
My present work showed that FASN overexpression contributes to the 
increased drug resistance phenotype in breast cancer cells. One advantage 
of increased FASN expression in cancer cells is to protect cells from 
anticancer drug-induced apoptosis through blocking caspase-8 activation. 
Future directions that may extend the current work are: 
1. FASN synthesizes palmitate, which is the precursor of many lipid 
molecules. FASN overexpression may affect the de novo synthesis or 
generation of some important lipid messengers that involves in regulation of 
cellular survival and apoptosis upon drug insult. As shown in this study, FASN 
overexpression inhibits the Adriamycin-induced ceramide production. It will be 
intresting to determine if FASN overexpression affects the level of other 
signaling lipids such as diacylglycerol (DAG), that promote cell survival 
(Bettaieb et al., 1999).  
2. In cancer cells, FASN mainly involves in the production of 
phospholipids partitioning into detergent resistant membrane microdomain 
(lipid raft aggregate). Lipid raft domains house many molecules involved in 
signal transduction, apoptosis, membrane transport, etc. Since FASN 
overexpression protects cancer cells from drug-induced apoptosis, it will be 
interesting to determine if there are any changes in membrane signaling 
molecules that either promote cell survival (such as growth factor receptors ) 
or apoptosis (such as the assembly of DISC). 
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